NASDAQ:REPL - Replimune Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Replimune Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.78 -0.19 (-1.91 %) (As of 04/2/2020 04:43 AM ET) Add Compare Today's Range$9.28Now: $9.78▼$9.8550-Day Range$8.90MA: $13.41▼$18.4552-Week Range$8.58Now: $9.78▼$19.66Volume76,600 shsAverage Volume104,684 shsMarket Capitalization$358.40 millionP/E RatioN/ADividend YieldN/ABeta2.73 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:REPL Previous Symbol CUSIPN/A CIKN/A Webhttp://www.replimune.com/ Phone781-222-9600Debt Debt-to-Equity Ratio0.20 Current Ratio13.43 Quick Ratio13.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.36 per share Price / Book2.24Profitability EPS (Most Recent Fiscal Year)($1.33) Net Income$-30,830,000.00 Net MarginsN/A Return on Equity-29.68% Return on Assets-24.86%Miscellaneous Employees62 Outstanding Shares36,646,000Market Cap$358.40 million Next Earnings Date6/26/2020 (Estimated) OptionableNot Optionable Receive REPL News and Ratings via Email Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:REPL Rates by TradingView Replimune Group (NASDAQ:REPL) Frequently Asked Questions How has Replimune Group's stock been impacted by COVID-19 (Coronavirus)? Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPL shares have decreased by 18.0% and is now trading at $9.78. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Replimune Group? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Replimune Group. When is Replimune Group's next earnings date? Replimune Group is scheduled to release its next quarterly earnings announcement on Friday, June 26th 2020. View our earnings forecast for Replimune Group. How were Replimune Group's earnings last quarter? Replimune Group Inc (NASDAQ:REPL) released its earnings results on Thursday, February, 13th. The company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.10. View Replimune Group's earnings history. What price target have analysts set for REPL? 5 equities research analysts have issued 12 month price targets for Replimune Group's shares. Their forecasts range from $12.50 to $30.00. On average, they expect Replimune Group's stock price to reach $24.10 in the next twelve months. This suggests a possible upside of 146.4% from the stock's current price. View analysts' price targets for Replimune Group. What are Wall Street analysts saying about Replimune Group stock? Here are some recent quotes from research analysts about Replimune Group stock: 1. According to Zacks Investment Research, "Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. " (2/20/2020) 2. Chardan Capital analysts commented, "We expect the 4Q19 data from the phase I portion, potentially at the Cancer (SITC) annual meeting in November, will focus on safety and early signals of immune activity of RP1 as a single agent and in the combo setting. Per management, the company plans to accumulate data from the phase II cohorts over the next ~6 months and begin reporting on a per cohort basis over 2020 (consistent with prior timelines). RP1 trial, a registration-directed randomized controlled study in cutaneous squamous cell carcinoma (CSCC) +/- Regeneron’s (unrated) anti-PD1 cemiplimab is expected to begin in August. Replimune ended the quarter with $120.8 mm in cash, cash equivalents and short-term investments. This provides the company with a cash runway into calendar year 2H21." (8/15/2019) Has Replimune Group been receiving favorable news coverage? News stories about REPL stock have been trending very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Replimune Group earned a news impact score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutReplimune Group. Are investors shorting Replimune Group? Replimune Group saw a drop in short interest during the month of February. As of February 28th, there was short interest totaling 685,300 shares, a drop of 5.8% from the February 13th total of 727,600 shares. Based on an average daily volume of 118,200 shares, the short-interest ratio is presently 5.8 days. Currently, 5.0% of the company's shares are short sold. View Replimune Group's Current Options Chain. Who are some of Replimune Group's key competitors? Some companies that are related to Replimune Group include Cortexyme (CRTX), Bill.com (RVMD), Regenxbio (RGNX), SpringWorks Therapeutics (SWTX), Coherus Biosciences (CHRS), Editas Medicine (EDIT), Twist Bioscience (TWST), I-Mab (BDTX), Beam Therapeutics (BEAM), NanoString Technologies (NSTG), Adverum Biotechnologies (ADVM), Krystal Biotech (KRYS), Sangamo Therapeutics (SGMO), Novavax (NVAX) and Oyster Point Pharma (OYST). What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Peabody Energy (BTUUQ), Myovant Sciences (MYOV), Amarin (AMRN), Fate Therapeutics (FATE), Dell (DELL), Energy Transfer LP Unit (ET), Pfizer (PFE), Exxon Mobil (XOM) and Axsome Therapeutics (AXSM). Who are Replimune Group's key executives? Replimune Group's management team includes the following people: Mr. Philip Astley-Sparke, Exec. Chairman, Sec. & Treasurer (Age 48)Dr. Robert Coffin, Pres, CEO & Director (Age 54)Dr. Colin Love, Chief Operating Officer (Age 61)Dr. Pamela Esposito, Chief Bus. Officer (Age 45)Stephen Gorgol, Chief Accounting Officer When did Replimune Group IPO? (REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What is Replimune Group's stock symbol? Replimune Group trades on the NASDAQ under the ticker symbol "REPL." How do I buy shares of Replimune Group? Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Replimune Group's stock price today? One share of REPL stock can currently be purchased for approximately $9.78. How big of a company is Replimune Group? Replimune Group has a market capitalization of $358.40 million. The company earns $-30,830,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Replimune Group employs 62 workers across the globe. View additional information about Replimune Group. What is Replimune Group's official website? The official website for Replimune Group is http://www.replimune.com/. How can I contact Replimune Group? Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected] MarketBeat Community Rating for Replimune Group (NASDAQ REPL)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 105 (Vote Outperform)Underperform Votes: 130 (Vote Underperform)Total Votes: 235MarketBeat's community ratings are surveys of what our community members think about Replimune Group and other stocks. Vote "Outperform" if you believe REPL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/2/2020 by MarketBeat.com StaffFeatured Article: FAANG Stocks
